Reify Health has secured $220.0 million in new funding from investors, marking a significant capital infusion for the company dedicated to transforming clinical trials. Reify Health is focused on making clinical trials faster, more predictable, and more accessible. Through its business entities, OneStudyTeam and Care Access, the company provides best-in-class trial optimization software and transformative clinical trial infrastructure that delivers research directly to more healthcare providers, communities, and patients wherever they are.
This substantial investment will enable Reify Health to accelerate its mission and expand its operational capabilities. The company plans to strategically deploy the funds to further develop its trial optimization software and enhance its clinical trial infrastructure. This capital will support continued growth initiatives, allowing Reify Health to deepen its partnerships with top biopharma companies, thousands of research clinics worldwide, and leading healthcare and community organizations.
The funding underscores investor confidence in Reify Health's approach to improving the efficiency and reach of clinical research. By strengthening its technological offerings and expanding its network, Reify Health aims to continue its work in bringing new medicines to patients more rapidly, one trial at a time. The company is poised to further its impact on the landscape of clinical research, reinforcing its commitment to innovation and accessibility in healthcare.
